Patients receiving oral disopyramide should be closely monitored for QTc prolongation and ventricular tachyarrhythmias.
May signal delayed proarrhythmia risk on chronic disopyramide; leaves open incidence and monitoring needs in broader cohorts.
A patient presenting with atypical ventricular tachycardia due to oral disopyramide given in normal doses over a period of four months is described. This arrhythmia was preceded by marked prolongation of the QTc. It is suggested that patients receiving treatment with oral disopyramide should be closely monitored for symptoms of ventricular tachyarrhythmias, particularly in the face of a prolonged QTc.
No takes yet. Share an insight, caveat, or question.
B.L. Chia (1980) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: